87 related articles for article (PubMed ID: 1687102)
1. The over-expression of P-glycoprotein in K-562 and DAUDI cells, is associated with a high susceptibility to NK and LAK cells.
Dupuis ML; Ramoni C; Yassen A; Samoggia P; Tombesi M; Caserta M; Cianfriglia M
J Biol Regul Homeost Agents; 1991; 5(4):137-41. PubMed ID: 1687102
[TBL] [Abstract][Full Text] [Related]
2. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
3. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of multidrug-resistant human T-lymphoblastoid CEM cell line to cell-mediated cytolysis.
Ramoni C; Dupuis ML; Cenciarelli C; Ciccolini F; Cianfriglia M
Ann Ist Super Sanita; 1990; 26(3-4):433-9. PubMed ID: 1982604
[TBL] [Abstract][Full Text] [Related]
5. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
6. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
Treichel RS; Olken S
Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
[TBL] [Abstract][Full Text] [Related]
7. Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma.
Savas B; Kerr PE; Ustun H; Cole SP; Pross HF
Anticancer Res; 1998; 18(6A):4355-61. PubMed ID: 9891492
[TBL] [Abstract][Full Text] [Related]
8. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
Komatsu F; Kajiwara M
Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
[TBL] [Abstract][Full Text] [Related]
9. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
Furbert-Harris PM; Evans CH
Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells.
Schmidt-Wolf IG; Lefterova P; Johnston V; Scheffold C; Csipai M; Mehta BA; Tsuruo T; Huhn D; Negrin RS
Cell Immunol; 1996 Apr; 169(1):85-90. PubMed ID: 8612299
[TBL] [Abstract][Full Text] [Related]
11. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
Klasa RJ; Silver HK; Kong S
Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
[TBL] [Abstract][Full Text] [Related]
12. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition.
Mueller EA; Anderer FA
Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765
[TBL] [Abstract][Full Text] [Related]
13. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue.
Donskov F; Basse PH; Hokland M
Nat Immun; 1996-1997; 15(2-3):134-46. PubMed ID: 9162263
[TBL] [Abstract][Full Text] [Related]
14. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
15. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
16. [Human LAK cell induction and its biological characteristics].
Wu YY
Zhonghua Zhong Liu Za Zhi; 1990 Jul; 12(4):254-7. PubMed ID: 2125554
[TBL] [Abstract][Full Text] [Related]
17. Decrease of lymphokine (interleukin-2)-activated killer activity in peripheral blood after administration of natural interferon-gamma.
Yanagawa H; Sone S; Okubo A; Fukuta K; Nishioka Y; Ogura T
Jpn J Clin Oncol; 1990 Dec; 20(4):356-63. PubMed ID: 2126575
[TBL] [Abstract][Full Text] [Related]
18. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells.
Kimmig A; Gekeler V; Neumann M; Frese G; Handgretinger R; Kardos G; Diddens H; Niethammer D
Cancer Res; 1990 Nov; 50(21):6793-9. PubMed ID: 1698543
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein-mediated multidrug resistance and cytotoxic effector cells.
Savas B; Cole SP; Akoglu TF; Pross HF
Nat Immun; 1992; 11(4):177-92. PubMed ID: 1358293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
